Rebound disease activity reduction in relapsing multiple sclerosis patients transitioned from natalizumab to teriflunomide

被引：0
|
作者：
Cohan, S. [1 ]
Edwards, K. [2 ]
Chen, C. [3 ]
Gervasi, T. [3 ]
O'Connor, J. [2 ]
Smoot, K. [1 ]
Kresa-Reahl, K. [1 ]
机构：
[1] Providence Hlth & Serv, Providence Multiple Sclerosis Ctr, Providence, RI USA
[2] MS Ctr Northeastern New York, Latham, NY USA
[3] Providence Hlth & Serv, Providence Brain & Spine Inst, Providence, OR USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P655
引用
收藏
页码：313 / 313
页数：1
相关论文
共 50 条
  • [1] Rebound Disease Activity Reduction in Relapsing Multiple Sclerosis Patients Transitioned From Natalizumab to Teriflunomide
    Cohan, Stanley
    Edwards, Keith R.
    Chen, Chiayi
    Gervasi, Tiffany
    O'Connor, Judy
    Smoot, Kyle
    Kresa-Reahl, Kiren
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 70 - 70
  • [2] Reducing Rebound Disease Activity in Relapsing Multiple Sclerosis Patients Electively Transitioned from Natalizumab to Teriflunomide
    Cohan, Stanley
    Edwards, Keith
    Gervasi, Tiffany
    Chen, Chiayi
    O'Connor, Judy
    Smoot, Kyle
    Kresa-Reahl, Kiren
    NEUROLOGY, 2017, 88
  • [3] Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
    Cohan, Stanley L.
    Edwards, Keith
    Lucas, Lindsay
    Gervasi-Follmar, Tiffany
    O'Connor, Judy
    Siuta, Jessica
    Kamath, Vineetha
    Garten, Lore
    Chen, Chiayi
    Thomas, James
    Smoot, Kyle
    Kresa-Reahl, Kiren
    Spinelli, Kateri J.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (01)
  • [4] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [5] Disease activity after natalizumab discontinuation in multiple sclerosis: reactivation or rebound?
    Borriello, G.
    Prosperini, L.
    Mancinelli, C.
    Fubelli, F.
    Gianni, C.
    Marinelli, F.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S228 - S228
  • [6] Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
    John, Nevin
    Carroll, Antonia
    Brownlee, Wallace J.
    Chataway, Jeremy
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : 1376 - +
  • [7] Natalizumab Rebound in Multiple Sclerosis
    Lee, Joshua D.
    Chen, Tychicus
    NEUROHOSPITALIST, 2022, 12 (01): : 197 - 198
  • [8] Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
    Andrew Chan
    Jérôme de Seze
    Manuel Comabella
    CNS Drugs, 2016, 30 : 41 - 51
  • [9] Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis
    Galetta, Steven
    Calabresi, Peter
    Confavreux, Christian
    Giovannoni, Gavin
    Havrdova, Eva
    Hutchinson, Michael
    Kappos, Ludwig
    Lublin, Fred
    Miller, David
    O'Connor, Paul W.
    Phillips, J.
    Polman, Chris
    Radue, Ernst-Wilhelm
    Rudick, Richard
    Stuart, William
    Wojgt, Andrzej
    Weinstock-Guttman, Bianca
    Wynn, Daniel
    Pace, Amy
    Hyde, Robert
    Kim, Richard
    Panzara, Michael
    NEUROLOGY, 2008, 70 (11) : A89 - A90
  • [10] Natalizumab for relapsing multiple sclerosis
    Tenser, RB
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2387 - 2387
12345